120 related articles for article (PubMed ID: 38876181)
1. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.
Christofides EA; Stankiewicz A; Denham D; Bellido D; Franek E; Nakhle S; Łukaszewicz M; Reed J; Cózar-León V; Kosch C; Karaś P; Fitz-Patrick D; Handelsman Y; Warren M; Hollander P; Huffman D; Raskin P; Oroszlán T; Lillestol M; Ovalle F
Endocr Pract; 2024 Jun; ():. PubMed ID: 38876181
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Christofides EA; Puente O; Norwood P; Denham D; Maheshwari H; Lillestol M; Hart T; Nakhle S; Chadha A; Fitz-Patrick D; Sugimoto D; Soufer J; Young D; Warren M; Huffman D; Reed J; Bays H; Arora S; Rizzardi B; Tidman R; Rendell M; Johnson KA
Diabetes Obes Metab; 2024 Jun; 26(6):2412-2421. PubMed ID: 38558508
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog
Blevins TC; Raiter Y; Sun B; Donnelly C; Shapiro R; Chullikana A; Rao A; Vashishta L; Ranganna G; Barve A
BioDrugs; 2022 Nov; 36(6):761-772. PubMed ID: 36114990
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus
Yan X; Feng C; Lou Y; Zhou Z
Diabetes Ther; 2022 Jun; 13(6):1161-1174. PubMed ID: 35471721
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
7. [
Zhang TT; Liu XM; Shi BY; Wang CJ; Mo ZH; Liu Y; Shan ZY; Yang WY; Li QM; Lyu XF; Yang JK; Xue YM; Zhu DL; Shi YQ; Huang Q; Zhou ZG; Wang Q; Ji QH; Li YB; Gao X; Lu JM; Zhang JQ; Guo XH
Zhonghua Nei Ke Za Zhi; 2020 Dec; 59(12):960-967. PubMed ID: 33256337
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of MYL-1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study.
Blevins TC; Barve A; Raiter Y; Aubonnet P; Athalye S; Sun B; Muniz R
Diabetes Obes Metab; 2020 Mar; 22(3):365-372. PubMed ID: 31691472
[TBL] [Abstract][Full Text] [Related]
10. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
[No Abstract] [Full Text] [Related]
11. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes.
Home P; Derwahl KM; Ziemen M; Wernicke-Panten K; Pierre S; Kirchhein Y; Garg SK
Diabetes Technol Ther; 2018 Feb; 20(2):160-170. PubMed ID: 29355435
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.
Wang W; Song X; Lou Y; Du L; Zhu D; Zhou Z
Diabetes Obes Metab; 2022 Jun; 24(6):1094-1104. PubMed ID: 35187770
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
[TBL] [Abstract][Full Text] [Related]
14. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial.
Yan X; Jiang S; Lou Y; Zhou Z
Diabetes Obes Metab; 2021 Oct; 23(10):2226-2233. PubMed ID: 34121308
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
Blevins TC; Dahl D; Rosenstock J; Ilag LL; Huster WJ; Zielonka JS; Pollom RK; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):726-33. PubMed ID: 25974640
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study.
Blevins TC; Barve A; Sun B; Raiter Y; Aubonnet P; Muniz R; Athalye S; Ankersen M
Diabetes Obes Metab; 2019 Jan; 21(1):129-135. PubMed ID: 30112792
[TBL] [Abstract][Full Text] [Related]
18. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study).
Rosenstock J; Hollander P; Bhargava A; Ilag LL; Pollom RK; Zielonka JS; Huster WJ; Prince MJ
Diabetes Obes Metab; 2015 Aug; 17(8):734-41. PubMed ID: 25931141
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes.
Tarigan TJE; Dwijayanti A; Setyowati S; Louisa M
Diabetes Metab Syndr Obes; 2021; 14():107-116. PubMed ID: 33469328
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
Shah VN; Franek E; Wernicke-Panten K; Pierre S; Mukherjee B; Sadeharju K
Diabetes Ther; 2021 Feb; 12(2):557-568. PubMed ID: 33432547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
